Trending Stock News

Athersys, Inc. (ATHX) EPS Estimated At $-0.08; Last Week Norcros plc (LON:NXR) Coverage

Analysts expect Athersys, Inc. (NASDAQ:ATHX) to report $-0.08 EPS on March, 8.They anticipate $0.02 EPS change or 20.00% from last quarter’s $-0.1 EPS. After having $-0.06 EPS previously, Athersys, Inc.’s analysts see 33.33% EPS growth. The stock decreased 3.88% or $0.0636 during the last trading session, reaching $1.5764. About 477,723 shares traded. Athersys, Inc. (NASDAQ:ATHX) has declined 32.11% since February 9, 2017 and is downtrending. It has underperformed by 48.81% the S&P500.

Among 4 analysts covering Norcros PLC (LON:NXR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Norcros PLC had 13 analyst reports since November 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by Numis Securities given on Thursday, April 14. Canaccord Genuity maintained it with “Buy” rating and GBX 335 target in Monday, November 27 report. The firm has “Buy” rating by Numis Securities given on Tuesday, December 8. As per Thursday, November 17, the company rating was maintained by Numis Securities. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, July 6 report. The company was maintained on Friday, April 1 by Cantor Fitzgerald. On Tuesday, October 11 the stock rating was maintained by Numis Securities with “Buy”. As per Tuesday, June 14, the company rating was maintained by Numis Securities. The firm earned “Buy” rating on Tuesday, December 12 by Numis Securities. FinnCap maintained Norcros plc (LON:NXR) on Friday, January 22 with “Buy” rating. See Norcros plc (LON:NXR) latest ratings:

12/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
27/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: GBX 315.00 New Target: GBX 335.00 Reiteration

Norcros plc, together with its subsidiaries, develops, makes, markets, and exports home consumer products in the United Kingdom, South Africa, and internationally. The company has market cap of 143.51 million GBP. The firm makes and distributes electric, and mixer showers and accessories under the Triton brand name; taps, mixer showers, bathroom accessories, and valves under the Vado brand name; and bathroom furnishings and accessories under the Croydex brand name. It has a 14.48 P/E ratio. It also offers kitchen taps, sinks, bathroom brassware, and showering solutions under the Abode brand name; ceramic wall and floor tiles under the Johnson Tiles brand name; and adhesives, grouts, and surface preparation products under the Norcros Adhesives brand name for fixing ceramic and porcelain tiles, mosaics, natural stones, and marbles.

Investors sentiment decreased to 0.53 in 2017 Q3. Its down 1.33, from 1.86 in 2017Q2. It dived, as 3 investors sold Norcros plc shares while 12 reduced holdings. 2 funds opened positions while 6 raised stakes. 1.09 million shares or 6.32% less from 1.16 million shares in 2017Q2 were reported. Guggenheim Capital Ltd Llc invested in 0% or 44,300 shares. Raymond James And has invested 0% in Norcros plc (LON:NXR). Raymond James Fin Service Advsr has invested 0% in Norcros plc (LON:NXR). Moreover, Benjamin F Edwards has 0% invested in Norcros plc (LON:NXR) for 695 shares. Commercial Bank Of America Corp De holds 74,835 shares or 0% of its portfolio. 168,656 were accumulated by Tortoise Investment Mngmt Limited Liability Company. Tradewinds Capital Mgmt Lc invested in 1,438 shares. Parametric Portfolio Assocs Ltd Company has invested 0% in Norcros plc (LON:NXR). Cap Advsrs Limited Company reported 0.03% of its portfolio in Norcros plc (LON:NXR). Pnc Fincl Group Incorporated stated it has 7,504 shares or 0% of all its holdings. Landscape Mgmt Ltd Liability Com stated it has 16,850 shares or 0.03% of all its holdings. Wells Fargo & Mn stated it has 0% in Norcros plc (LON:NXR). Rocky Mountain Advisers Ltd holds 0.03% or 500 shares. Brown Brothers Harriman And Company holds 0% or 1,000 shares. & Mngmt Gru Ltd holds 0.27% or 53,000 shares.

It closed at GBX 179.5 lastly. It is down 0.00% since February 9, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 3.06 in Q3 2017. Its up 0.82, from 2.24 in 2017Q2. It improved, as 5 investors sold Athersys, Inc. shares while 12 reduced holdings. 23 funds opened positions while 29 raised stakes. 49.65 million shares or 129.17% more from 21.67 million shares in 2017Q2 were reported. Glenmede Com Na has 0% invested in Athersys, Inc. (NASDAQ:ATHX) for 22,500 shares. Tower Capital Limited Liability Com (Trc) owns 15,558 shares. Jane Street Grp Llc stated it has 40,296 shares or 0% of all its holdings. National Planning accumulated 0% or 10,000 shares. 530,530 were accumulated by Mckinley Cap Management Limited Liability Delaware. State Common Retirement Fund holds 0% or 77,600 shares in its portfolio. Two Sigma Ltd Com stated it has 0.01% in Athersys, Inc. (NASDAQ:ATHX). 15,000 are owned by Ferguson Wellman Cap Mngmt. Bnp Paribas Arbitrage invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). State Board Of Administration Of Florida Retirement, Florida-based fund reported 16,400 shares. Moreover, Perkins Capital has 0.67% invested in Athersys, Inc. (NASDAQ:ATHX) for 308,725 shares. Bancshares Of New York Mellon reported 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Metropolitan Life Insurance reported 78,263 shares or 0% of all its holdings. Alliancebernstein L P holds 0% or 58,900 shares in its portfolio. Old Mutual Glob (Uk) has 130,797 shares.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company has market cap of $194.81 million. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. It currently has negative earnings. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers.

Among 2 analysts covering Athersys Inc (NASDAQ:ATHX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Athersys Inc had 3 analyst reports since December 22, 2015 according to SRatingsIntel. Maxim Group maintained Athersys, Inc. (NASDAQ:ATHX) on Monday, August 7 with “Buy” rating.

Leave a Reply

Your email address will not be published. Required fields are marked *